Comparative Pharmacology
Head-to-head clinical analysis: MEPRON versus METUBINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPRON versus METUBINE IODIDE.
MEPRON vs METUBINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
It is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain in Plasmodium species, specifically at the cytochrome bc1 complex (Complex III), leading to collapse of mitochondrial membrane potential and inhibition of pyrimidine synthesis.
Nondepolarizing neuromuscular blocking agent; competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing depolarization and muscle contraction.
750 mg orally twice daily with food for 21 days for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia. For prophylaxis: 1500 mg orally once daily with food.
0.1-0.3 mg/kg IV as a single dose for neuromuscular blockade during surgery. Additional doses of 0.03-0.05 mg/kg at 25-30 minute intervals as needed.
None Documented
None Documented
Mean terminal elimination half-life is 2.2-3.2 days (approximately 53-77 hours) in adults; prolonged in hepatic impairment (up to 22 days) and in elderly (up to 5 days).
Terminal elimination half-life: approximately 2-3 minutes (due to rapid redistribution from plasma to tissues), with a longer terminal phase (30-60 minutes) reflecting slow efflux from deep compartments.
Primarily fecal (87-94%) via bile; renal excretion accounts for <1% as unchanged drug. A minor metabolite, atovaquone glucuronide, is excreted in urine.
Primarily renal excretion of unchanged drug (approximately 70-80% over 24 hours); biliary/fecal excretion accounts for <10%.
Category C
Category C
Antiprotozoal
Antiprotozoal